lung cancer

[Cell] Investigators found that in Tgfbr2 knockout tumors, the tumor microenvironment (TME) was converted to a fibro-mucinous state, and T cells excluded, concomitant with upregulated TGFβ and TGFβ-mediated fibroblast activation, indicating that TGFβ-receptor loss on cancer cells increased TGFβ bioavailability and its immunosuppressive effects on the TME.

[Cell Reports Medicine] Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.

[Cancer Immunology Immunotherapy] Large cohorts of non-small cell lung cancer patients from The Cancer Genome Atlas and a single-cell sequencing dataset were integrated to illustrate immunosuppressive phenotypes of tumor-associated macrophages, followed by experimental verification.

[Harpoon Therapeutics, Inc.] Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.

[Cell Death Discovery] Scientists analyzed the regulatory relationship of hypoxia and PVT1 and the mechanism of PVT1 in the hypoxia-induced chemoresistance process of lung cancer.

[EMBO Molecular Medicine] Investigators focused on the neuroendocrine SCLC subtypes, SCLC-A and SCLC-N, whose transcription addiction was driven by ASCL1 and NEUROD1 transcription factors which targeted E-box motifs to activate up to 40% of total genes.